The Lancet - Ocrelizumab in multiple sclerosis: risks and benefits, by Dr. Abhijit Chaudhuri

“...The lessons from the clinical trial of natalizumab4 seem to have been forgotten too quickly: nearly a quarter of more than 200 patients with natalizumab-induced progressive multifocal leukoencephalopathy are dead and most of the rest are severely disabled by the drug rather then their disease. Quo vadis multiple sclerosis?... I declare that I have no conflicts of interest.”

read more: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2960508-X/fulltext?rss=yes